Table II.
Patient characteristics.
| Patient | Sex | Age (years) | Diagnosis (morphological subtype) | Cytogenetics at diagnosis | Previous treatment | Disease status pre-trial |
|---|---|---|---|---|---|---|
| RFH 001 | Male | 61 | AML (M0) | 46, XY, t(1;2)(p32;p13) | ADE 3 + 10 (no response); FlAG-Ida (to CR); FlAG; MACE | Morphological CR1; MRD positive |
| RFH 002 | Female | 68 | AML (M1) | Failed | DA + GO (to CR); DA | CR1; low platelet count |
| RFH 003 | Female | 56 | Secondary AML (M5) | Normal | MDS RAEB-1 treated with FlAG (to CR1); DA; MACE; MidAC Relapsed with AML after 3 years: treated with FlAG; FlAG-Ida (to CR2); Bu/Cy ASCT. | CR2 |
| UCH 001 | Female | 64 | AML (M1) | Normal | DA × 1; LD ara-C × 3 | Stable PR; 15% blasts |
| UCH 002 | Female | 65 | AML (M1) | Normal | DA × 1; LD ara-C × 8 | PR; 15% blasts |
| UCH 003 | Female | 75 | AML (M4) | Normal | LD ara-C + GO × 2 (to CR); LD ara-C × 2 | CR1 |
| BHM 001 | Male | 66 | AML | 46, XY, der(7)t(7;11) (q22;q13) | DA × 1; MidAC × 2 | PR; slowly progressive |
| BHM 002 | Male | 68 | AML (M0) | Normal | DA × 2; MidAC × 1 | CR1 |
RFH, Royal Free Hospital, London; UCH, University College Hospital, London; BHM, Queen Elizabeth Hospital, Birmingham; AML, acute myeloid leukaemia; CR, complete remission; CR1, first CR; CR2, second CR; PR, partial remission; MRD, minimal residual disease; MDS RAEB-1, myelodysplastic syndrome refractory anaemia with excess blasts-1; ADE, daunorubicin, cytarabine and etoposide; Bu/Cy ASCT, busulfan and cyclophosphamide-conditioned autologous stem cell transplantation; DA, daunorubicin and cytarabine; FlAG, fludarabine, cytarabine and granulocyte colony-stimulating factor; GO, gemtuzumabozogamicin; Ida, idarubicin; LD ara-C, low-dose cytarabine; MACE, amsacrine, cytarabine and etoposide; MidAC, mitoxantrone and cytarabine.